Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of TMP/SMX Prophylaxis for PJP in AIIRD Patients
NCT06499233Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of trimethoprim + sulfamethoxazole in Pneumocystis jirovecii pneumonia (PJP) (4 arms), sponsored by Tongji Hospital. Primary endpoint: Number of participants with PJP infection at 12 months. Started Jul 2024; status: recruiting.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
Pneumocystis jirovecii pneumonia (PJP)
Beyond the preview
Go deeper on NCT06499233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06499233.